Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2023-07-17 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-07-17 English
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
Regulatory Filings Classification · 98% confidence The document is explicitly titled "FORM 6-K" and is filed with the "SECURITIES AND EXCHANGE COMMISSION". Form 6-K is the standard SEC filing used by Foreign Private Issuers to report material information that is required to be publicly disclosed in their home country or stock exchange, or that is distributed to their shareholders. This type of filing is generally used for current reports that do not fit neatly into the periodic reporting requirements of Form 20-F (Annual Report). Since the content is a press release announcing the initiation of a clinical trial and providing business updates, and it is submitted on Form 6-K, it falls under the category of general regulatory announcements that are not covered by the more specific categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). Therefore, the most appropriate classification is the general regulatory filing fallback category, RNS.
2023-07-17 English
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
Regulatory Filings Classification · 95% confidence The document is very short (2118 characters) and explicitly states that it is an 'Immediate Report' under Israeli regulations. Crucially, it contains the line: 'Attached hereto is a report on*BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial...' followed by a PDF filename. This structure indicates that the current document is an announcement *about* a report, rather than the full report itself. Since it is an immediate regulatory announcement that doesn't fit specific categories like DIV, DIRS, or ER, the most appropriate classification based on the 'MENU VS MEAL' rule and the general nature of regulatory updates is Regulatory Filings (RNS).
2023-07-17 English
Immediate Report of Meeting to be held on August 7, 2023, proxy statement
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a 'PROXY' solicited on behalf of the Board of Directors for the 'Annual General Meeting of Shareholders to be held on August 7, 2023'. It contains voting instructions for various resolutions typical of an AGM, such as the re-election of directors and approval of auditor reappointment. This content directly aligns with the materials distributed to shareholders to solicit their votes for the AGM, which corresponds to the Proxy Solicitation & Information Statement definition (PSI). While it relates to the AGM (AGM-R), the specific function of soliciting votes via a proxy card makes PSI the most precise classification.
2023-06-23 English
Immediate Report of Meeting to be held on August 7, 2023, proxy statement
AGM Information Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed by a 'FOREIGN PRIVATE ISSUER'. The content details the announcement of an 'Annual Meeting of Shareholders' scheduled for August 7, 2023, and includes the 'NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS' and the 'PROXY STATEMENT'. This material is specifically designed to inform shareholders and solicit their votes for the upcoming AGM. The most specific category for materials related to the Annual General Meeting, including the proxy statement and notice, is 'AGM Information' (AGM-R). While it is filed on a Form 6-K (which might suggest RNS), the primary purpose and content strongly align with AGM-R.
2023-06-23 English
Immediate Report of Meeting to be held on August 7, 2023, proxy statement
AGM Information Classification · 98% confidence The document explicitly states it is giving notice of the 'convening of meeting' for an 'annual meeting' scheduled for 07/08/2023. It details the agenda items, which primarily involve the re-election of directors and approval of CEO equity compensation, typical subjects for an Annual General Meeting (AGM). Although it mentions a 'Proxy Statement' in item 6, the core purpose of this filing is the formal announcement and scheduling of the meeting itself, which aligns best with the AGM-R (AGM Information) category, as it contains the materials/notice for the AGM.
2023-06-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.